Total Payments
$5,788
2024 Payments
$1,038
Companies
51
Transactions
263
Medicare Patients
2,152
Medicare Billing
$338,795
Payment Breakdown by Category
Food & Beverage$5,544 (95.8%)
Education$244.30 (4.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,544 | 256 | 95.8% |
| Education | $244.30 | 7 | 4.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $496.46 | 32 | $0 (2024) |
| PFIZER INC. | $421.22 | 14 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $383.49 | 22 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $310.96 | 8 | $0 (2024) |
| Celgene Corporation | $262.47 | 13 | $0 (2024) |
| Daiichi Sankyo Inc. | $260.18 | 10 | $0 (2024) |
| Amgen Inc. | $255.41 | 12 | $0 (2022) |
| Seattle Genetics, Inc. | $238.13 | 15 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $237.23 | 14 | $0 (2024) |
| Seagen Inc. | $211.00 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,038 | 32 | PFIZER INC. ($186.95) |
| 2023 | $430.33 | 17 | Seagen Inc. ($109.75) |
| 2022 | $806.41 | 34 | Amgen Inc. ($73.09) |
| 2021 | $543.21 | 23 | GlaxoSmithKline, LLC. ($115.85) |
| 2020 | $136.01 | 8 | AstraZeneca Pharmaceuticals LP ($36.00) |
| 2019 | $847.06 | 38 | Puma Biotechnology, Inc. ($151.13) |
| 2018 | $1,027 | 57 | Novartis Pharmaceuticals Corporation ($148.10) |
| 2017 | $959.58 | 54 | Merck Sharp & Dohme Corporation ($146.18) |
All Payment Transactions
263 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $31.95 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: Oncology | ||||||
| 11/19/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $42.05 | General |
| Category: DESMOID TUMORS | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $35.50 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $28.43 | General |
| Category: Hematology | ||||||
| 10/29/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $27.38 | General |
| Category: Immunology | ||||||
| 10/10/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: Oncology | ||||||
| 09/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $30.75 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $39.90 | General |
| Category: DESMOID TUMORS | ||||||
| 09/05/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $23.00 | General |
| 09/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $27.88 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: Oncology | ||||||
| 07/19/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $30.52 | General |
| Category: Immunology | ||||||
| 07/16/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.18 | General |
| Category: Oncology | ||||||
| 06/06/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $35.16 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: Oncology | ||||||
| 04/18/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $28.90 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 440 | 1,293 | $159,948 | $57,201 |
| 2022 | 10 | 557 | 6,790 | $291,354 | $101,315 |
| 2021 | 9 | 614 | 6,687 | $298,980 | $105,520 |
| 2020 | 9 | 541 | 4,266 | $201,134 | $74,759 |
Total Patients
2,152
Total Services
19,036
Medicare Billing
$338,795
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 100 | 205 | $79,540 | $29,027 | 36.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 64 | 85 | $24,650 | $8,593 | 34.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 46 | 46 | $25,208 | $8,289 | 32.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 30 | 46 | $9,200 | $3,320 | 36.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 63 | 326 | $9,454 | $2,481 | 26.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 69 | 308 | $2,740 | $2,349 | 85.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 21 | 140 | $5,320 | $1,725 | 32.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 47 | 137 | $3,836 | $1,418 | 37.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 81 | 187 | $72,556 | $28,033 | 38.6% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2022 | 14 | 4,360 | $87,200 | $27,421 | 31.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 101 | 166 | $48,140 | $18,108 | 37.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 51 | 51 | $27,948 | $9,335 | 33.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 48 | 68 | $13,600 | $4,972 | 36.6% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2022 | 11 | 660 | $13,860 | $4,261 | 30.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 80 | 488 | $14,152 | $3,744 | 26.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 62 | 223 | $6,244 | $2,323 | 37.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 28 | 143 | $5,434 | $1,802 | 33.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 81 | 444 | $2,220 | $1,316 | 59.3% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2021 | 17 | 4,720 | $94,460 | $32,415 | 34.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 107 | 212 | $61,480 | $22,457 | 36.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 80 | 146 | $56,648 | $21,483 | 37.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 61 | 61 | $33,428 | $10,614 | 31.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 64 | 110 | $22,000 | $8,332 | 37.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 91 | 532 | $15,428 | $4,134 | 26.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 69 | 226 | $6,328 | $2,387 | 37.7% |
About Dr. Himani Singh, MD
Dr. Himani Singh, MD is a Hematology & Oncology healthcare provider based in Oceanside, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/02/2008. The National Provider Identifier (NPI) number assigned to this provider is 1558546192.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Himani Singh, MD has received a total of $5,788 in payments from pharmaceutical and medical device companies, with $1,038 received in 2024. These payments were reported across 263 transactions from 51 companies. The most common payment nature is "Food and Beverage" ($5,544).
As a Medicare-enrolled provider, Singh has provided services to 2,152 Medicare beneficiaries, totaling 19,036 services with total Medicare billing of $338,795. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Oceanside, CA
- Active Since 01/02/2008
- Last Updated 03/07/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1558546192
Products in Payments
- KEYTRUDA (Biological) $467.36
- ADCETRIS (Biological) $305.73
- IBRANCE (Drug) $216.84
- Enhertu (Drug) $201.40
- OPDIVO (Biological) $190.63
- BRUKINSA (Drug) $164.27
- ENHERTU (Biological) $162.97
- Nerlynx (Drug) $151.13
- XPOVIO (Drug) $138.46
- TUKYSA (Drug) $137.46
- Kyprolis (Biological) $129.60
- Rubraca (Drug) $125.12
- BLENREP (Biological) $115.85
- FOUNDATIONONE (Device) $107.19
- Revlimid (Drug) $98.30
- CYRAMZA (Drug) $86.98
- ZEJULA (Drug) $84.94
- MEKINIST (Drug) $83.93
- REBLOZYL (Biological) $82.48
- OGSIVEO (Drug) $81.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.